Therefore, dual active H3R/M2Rantagonists were invented and described.2 Those dual active ligands (Chart 1) relates to the treatment of Alzheimer’s disease,attention deficit disorder, and autism. Here, HRH3 is linked to early-onset autosomal dominant Alzheimer disease.